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Mycobacterium avium subsp. paratuberculosis (MAP) is the etiologic agent of Johne’s
disease in ruminants causing chronic diarrhea, malnutrition, and muscular wasting.
Neonates and young animals are infected primarily by the fecal–oral route. MAP attaches
to, translocates via the intestinal mucosa, and is phagocytosed by macrophages. The
ensuing host cellular immune response leads to granulomatous enteritis characterized by
a thick and corrugated intestinal wall. We review various tissue culture systems, ileal loops,
and mice, goats, and cattle used to study MAP pathogenesis. MAP can be detected in
clinical samples by microscopy, culturing, PCR, and an enzyme-linked immunosorbent
assay. There are commercial vaccines that reduce clinical disease and shedding, unfortunately, their efficacies are limited and may not engender long-term protective immunity.
Moreover, the potential linkage with Crohn’s disease and other human diseases makes
MAP a concern as a zoonotic pathogen. Potential therapies with anti-mycobacterial
agents are also discussed. The completion of the MAP K-10 genome sequence has
greatly improved our understanding of MAP pathogenesis. The analysis of this sequence
has identified a wide range of gene functions involved in virulence, lipid metabolism,
transcriptional regulation, and main metabolic pathways. We also review the transposons
utilized to generate random transposon mutant libraries and the recent advances in the
post-genomic era. This includes the generation and characterization of allelic exchange
mutants, transcriptomic analysis, transposon mutant banks analysis, new efforts to generate comprehensive mutant libraries, and the application of transposon site hybridization
mutagenesis and transposon sequencing for global analysis of the MAP genome. Further
analysis of candidate vaccine strains development is also provided with critical discussions on their benefits and shortcomings, and strategies to develop a highly efficacious
live-attenuated vaccine capable of differentiating infected from vaccinated animals.
Keywords: Mycobacterium avium subsp. paratuberculosis, Johne’s disease, pathogenesis, transposon
mutagenesis, mutant bank

Abbreviations: MAP, Mycobacterium avium subsp. paratuberculosis; JD, Johne’s disease; MAH, M. avium subsp. hominissuis;
BMDM, blood-monocyte-derived macrophages; IL, interleukin; INF-γ, interferon-gamma; ELISA, enzyme-linked immunosorbent assay; CD, Crohn’s disease; TraSH, transposon site hybridization mutagenesis; Tn-Seq, transposon sequencing; DIVA,
differentiate vaccinated from infected animals.
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INTRODUCTION
Mycobacterium avium subsp. paratuberculosis (MAP) is the
etiologic agent of Johne’s disease (JD) in ruminants, a chronic
enteritis with significant economic impact and worldwide distribution (1). The potential linkage of MAP to Crohn’s disease
(CD) in humans continues to be intensively investigated with
dissimilar results (2–4). MAP was first isolated by the German
scientists Johne and Frothingham in 1895 (5). It causes disease
primarily in ruminants (cattle, sheep, goats, deer, etc.), but
there are also reports of infection in non-ruminants, especially
in wildlife (6). In the United States, annual losses to the cattle
industry have been estimated from $250 million (7) to $1.5
billion (8). A recent analysis of published data using a Bayesian
method (9), adjusting for sensitivity and specificity, determined
that the true United States dairy herd-level prevalence of MAP
was actually 91.1% compared to the 70.4% reported in 2007
(10). In beef cattle, herd-level prevalence of MAP is 7.9%
(11). Even though JD was first observed in the United States
in the early 1900s, the focus on research and disease control
has only increased in the past 20 years. A Voluntary Bovine
JD Control Program is in place to control JD on farms and
identify herds with a low risk of infection. Currently, one of
the most cost-effective and sensitive testing methods for JD is
the identification of MAP in herds by testing environmental
fecal samples by culturing from high traffic areas (9). Indeed,
the use of improved diagnostics coupled with good management practices have shown to decrease JD transmission (12).
Unfortunately, wildlife reservoirs may undermine efforts to
control JD in domesticated animals until their role in wildlife
is fully understood (13).

Figure 1 | Mycobacterium avium subsp. paratuberculosis (MAP) properties.
(A) Acid-fast stain of intestinal epithelium from an experimentally challenged
bovine reveals MAP (red rods) inside macrophages. (B) Electron microscopy
clearly shows the rod-shaped mycobacteria magnified over 50,000 times.

of MAP (20, 21). Since that time, mycobactin dependency has
been considered to be taxonomic for MAP. More recently, with
the genome sequence discussed further below, a molecular
understanding of mycobactin dependency has been discovered
by a deletion in the mbtA gene within the mycobactin synthesis
operon (22, 23).

PATHOGENESIS
Johne’s disease causes a chronic diarrhea characterized by a malabsorption syndrome that leads to malnutrition and muscular
wasting (Figure 2A). Neonates and juvenile animals are infected
mainly via the fecal–oral route. Transmission may also occur
by the consumption of milk and colostrum from infected cows
(24). Calves up to 6 months of age are at higher risk of getting
infected, but the risk of infection drops after this age (25). Mouse
models have shown that, after ingestion, MAP attachment to
and translocation through the intestinal mucosa is mediated by
both M-cells and enterocytes (26). Moreover, studies in tissue
cultures demonstrated that MAP affects the formation of tight
junctions in the intestinal mucosa providing a mechanism for
increased permeability (27). There is significant host–pathogen
crosstalk during this process as antigens 85 (28), 35 kDa (29),
MAP oxidoreductase (30), MAP fibronectin-binding protein
(31, 32), and the histone HupB (33) play important roles in
MAP epithelial cell adhesion and/or invasion. Previous findings
using a co-culture of the bovine mammary epithelial cell line
MAC-T (34) and bovine blood-monocyte-derived macrophages
(BMDM) suggest that phagosome acidification in MAP-infected
epithelial cells leads to interleukin (IL)-1β production, macrophage recruitment, and transepithelial migration (35). Bacilli
are subsequently phagocytosed by these sub- and intra-epithelial
macrophages (36–38). Once inside phagocytic cells, the ability of
MAP to survive and replicate within these phagocytic cells plays
a key role in pathogenesis (39, 40). Moreover, use of a culture
passage model showed that MAP lipid composition changes in
macrophages developing a pro-inflammatory phenotype (41).
The ensuing host cellular immune response leads to the typical granulomatous enteritis pathognomonic of JD (38), characterized by the thick and corrugated appearance of the intestinal

TAXONOMY AND PROPERTIES
Mycobacterium avium subsp. paratuberculosis is part of the
Mycobacterium avium complex in the genus Mycobacterium and
family Mycobacteriaceae. The M. avium complex contains two
clearly defined species M. avium and M intracellulare. M. avium
is classified into four subspecies based on the comprehensive
sequence-based analysis of the 16S-23S ribosomal RNA internal
transcribed spacer (14, 15): M. avium subsp. avium, M. avium
subsp. hominissuis (MAH), MAP, and M. avium subsp. silvati
cum. MAP is a facultative intracellular, Gram-positive, acid-fast
(Figure 1A) and small (0.5 × 1.5 μm) rod-shaped (Figure 1B)
bacterium. The cell wall is thick and waxy and made up of
mycolate and peptidoglycan layers held together by arabinogalactan. It is a slow-growing bacteria with a generation time of
over 20 h (16). Initial attempts to cultivate MAP in laboratory
media were unsuccessful (17) and it was hypothesized that the
inability of MAP to grow under in vitro conditions may be due
to the lack of some essential growth factor. Later, it was shown
that MAP was able to grow in media supplemented with extracts
from other mycobacteria (18, 19) and they concluded that MAP
lacked the ability to synthesize some essential growth factor that
is synthesized by other species. Mycobactin, an iron-binding
siderophore isolated from Mycobacterium phlei, was shown to
be the growth factor that is essential for the in vitro cultivation
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Figure 2 | Johne’s disease affected animal caused by Mycobacterium avium subsp. paratuberculosis. (A) Severely debilitated cow with common symptoms
of chronic diarrhea, malabsorption, muscular wasting, and malnutrition. The host cellular immune response leads to the typical granulomatous enteritis seen as
thickening of the (B) intestinal mucosa with prominent Peyer’s patches, and (C) lymph node showing hyperactive lymphoid tissue (white spots).

wall (Figure 2B) and inflamed lymph nodes (Figure 2C). Tissue
macrophages and dendritic cells play a crucial role in the
recognition of pathogen-associated molecular patterns in the
innate phase via toll-like receptors (42), as well as in antigen
processing and the elicitation of cytokine-mediated cellular
interactions (43). Control of MAP infections are dependent on
a T helper cell, Th1, type response and the subsequent activation of macrophages by interferon-gamma (INF-γ) secreted by
Th1 T lymphocytes in the acquired immunity phase (44, 45).
The killing mechanism of these activated phagocytic cells
involves the generation of nitric oxide by the inducible nitric
oxide synthase, whose activity has been already demonstrated in
cattle (46). In this context, the overproduction of nitric oxide is
particularly high in BMDM isolated from subclinically infected
animals (47). However, MAP also affects the function of bovine
macrophages as evidenced by unique mRNA expression profiles
(48), inhibition of apoptosis and antigen presentation (49), and
patterns of cytokine expression that have diagnostic significance
(50). Predominantly, MAP drives T helper cells from infected
cattle to undergo a Th2 response with enhanced expression of
IL-4, IL-5, IL-10, and inhibitors of tissue remodeling factors
(51, 52). This humoral response was confirmed in a neonatal
calf model (53). Other findings also implicate regulatory T and
Th17 cells in the immunopathogenesis of JD in both ruminants
and wildlife (49, 54).
Several models have been developed to study MAP pathogenesis. However, MAP elicits responses from the ruminant
host immune system that are not manifested in traditional
in vitro models. For example, in infected BMDM, MAP bacilli
multiply over 4–8 days (44, 55), but infection of the murine J774
macrophage cell line results in a decrease in bacterial loads over
time (56, 57). Thus, primary phagocytic cells are preferred to
conduct experiments when studying the interaction of MAP
with phagocytic cells. A promising systems biology approach
based on ileal loops has been developed to follow MAP infection from early to late stages (58). Recently, this model has
been applied to compare the host transcriptome profile upon
M. avium subsp. avium and MAP infection. Analysis of cellular
pathways affected during MAP infection was consistent with
intestinal mucosal weakening, the activation of a Th2 response,
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and phagocytosis inhibition that was not observed with M.
avium subsp. avium (59).

DIAGNOSIS AND CONTROL
Infected animals shed MAP in the feces before showing any
clinical signs, thus acting as a major source of infection to other
animals in the herd. Early diagnosis of the infection is very
important to prevent the spread of JD. Various diagnostic tests
were developed based on the direct and indirect detection of
MAP (60). The direct detection of MAP in clinical samples can be
accomplished by (i) microscopy, (ii) MAP isolation by culturing,
and (iii) the identification of MAP DNA by PCR. Ziehl–Neelsen
or acid-fast staining has been used for the examination of clinical
samples (Figure 1A). Acid-fast staining is the simplest, fastest,
and most economical method of diagnosis, but the specificity
and sensitivity are low as it is difficult to differentiate between
MAP and other acid-fast bacilli (61). Ziehl–Neelsen staining
can be used for the initial screening of MAP, but it has to be
confirmed by other specific tests, such as PCR and/or immunoassays. The isolation of MAP by culturing is the “gold standard”
for JD diagnosis. The dependence of MAP on mycobactin J
for growth in specialized laboratory media can also be used
to discriminate MAP from other acid-fast bacilli. Recently, an
improved growth medium was described that improves MAP
recoverability and sensitivity by 1,000-fold (62). Culture-based
diagnosis is very time consuming as MAP grows extremely slow
(6–8 weeks for colony formation on solid media). Therefore, a
very rapid and sensitive PCR-based testing was used for MAP
detection in clinical and environmental samples (63–65). This
PCR utilizes primers for a 1.4 kb multicopy insertion element,
IS900, which is sequence specific to MAP (60, 66). However, the
presence of IS900-like insertion sequences in other mycobacteria
was shown to compromise the specificity of this assay leading to
false-positive results (64, 67). To overcome false-positive results,
multiplex PCR based on the IS900, IS901, IS1245, and dnaJ gene
has been developed, but the sensitivity of this test is low due
to reagent interference and primer dimer formation (60, 68).
In addition, PCR assays with fecal samples are only 70% sensitive and 85% specific (69). Some good progress has been made
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identifying and using more specific targets for PCR tests (70–72),
and this comparative genomic approach has filled a knowledge
gap in MAP diagnostics. Some of these targets have even been
used in commercial diagnostic kits.
Diagnostic MAP assays created on the indirect detection are
based on the host immune response to infection. The delayedtype hypersensitivity skin test has been developed using a
Johnin purified protein derivative (73). However, this test is not
specific as other environmental mycobacteria can also sensitize
the animal and give false-positive results. So delayed-type
hypersensitivity skin tests cannot distinguish vaccinated from
naturally infected animals. As stated previously, MAP infection leads to a T helper cell response which secrets INF-γ. The
measurement of this INF-γ level by an enzyme-linked immunosorbent assay (ELISA) can also be used for the diagnosis of
JD using day-old blood sample culture supernatants stimulated
with Johnin and co-stimulated with bovine IL-12 and/or human
IL-2 (74). Unfortunately, MAP purified protein derivatives are
also used as antigens in the INF-γ assay leading to problems
with cross-reactivity. The cell wall lipopeptide, L5P, has been
studied as an alternative MAP antigen for the assay, but the
INF-γ response has been shown to be lower than with Johnin
(75). Thus, routinely used methods for MAP diagnosis include
the detection of antibodies in serum and milk from infected
animals using a commercial ELISA kit: (i) HerdCheck M. para
tuberculosis ELISA (IDEXX Laboratories, Inc.), (ii) ParaCheck
(CSL/Biocor), (iii) SERELISA ParaTB (Synbiotic Corp.), and
(iv) ID Screen® Paratuberculosis Indirect (IDvet Genetics).
Compared to PCR diagnosis, an ELISA has a lower sensitivity
of 50%, but a much greater specificity of 99.8% (76, 77). More
studies are required to identify MAP specific antigens to develop
immune-based assays for diagnosis of JD that have a higher level
of sensitivity.
Control measures to prevent JD include vaccination (the most
cost-effective), testing, and improved herd management based
on a producer’s resources, facilities, and operation (78). Unfor
tunately, though there are JD vaccines that reduce clinical disease
and shedding, their efficacies are limited and none afford longterm protective immunity. For example, in the United States,
Mycopar® (Boehringer Ingelheim Vetmedica, Inc.) is the only
licensed vaccine against JD in cattle. However, this vaccine was
derived from M. avium subsp. avium strain 18 (79) and; therefore,
does not have an optimal antigenic repertoire. Another bacterin,
Silirum® (Zoetis Animal Health) is being tested in Australia
and approved for limited use in cattle. This vaccine contains the
heat-killed MAP 316F strain. This formulation may possess a
better antigenic repertoire, but while using heat-killed bacteria
may improve safety, it may also reduce efficacy. Neoparasec®
(Rhone-Merieux) contains the live-attenuated MAP strain 316F
while Gudair® (Zoetis Animal Health) is heat-killed 316F and
both are licensed for use in sheep and goats. However, current
vaccines cannot distinguish vaccinated from infected animals,
thus compromising JD diagnostic tests (80), and strain 316F
was generated in the 1920s by random attenuation procedures
(e.g., passages on ox bile) that are only now being investigated
(81). In the final analysis, a vaccine of high efficacy is needed to
significantly control JD (82).
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Testing results on the new generation of human anti-tuberculosis
vaccines seem to indicate that live-attenuated vaccines provide
better protection than subunit vaccines (83). As JD is caused by
a Mycobacterium, it is likely that a similar situation will occur for
candidate subunit or bacterin-based vaccines. This was actually
the impetus behind the JD Integrated Program—Animal and
Plant Health Inspection Service efforts to undertake a standardized vaccine test program. United States and New Zealand
researchers contributed 22 blinded live-attenuated vaccine
candidates to be evaluated in a three-phase study: BMDM,
mouse, and goat models. Though the methodology for animal
testing was well developed (84), most of the attenuated transposon mutants tested were first-generation ones and carried the
Tn5367 transposase which lead to instability. Moreover, there
were unknowns that could not be ascertained before the start
of the trial, such as the best immunization route and dosing
schedule. Nonetheless, important data and reagents were developed (80). It may still be possible to develop a subunit vaccine
capable of controlling infections by eliciting the appropriate type
of humoral immunity (85), especially against antigens expressed
in the pro-inflammatory phenotype (86).

ZOONOTIC POTENTIAL
Mycobacterium avium subsp. paratuberculosis is among a list of
pathogens that have been associated withCD, a human chronic
inflammatory bowel disease (2, 87, 88). The cross-reactivity of
MAP antigens with those in humans, such as the zinc transporter
8 protein, may underlie the etiology of these diseases (89). MAP is
also postulated to be involved in the progression of HIV infection
and other immune dysfunction diseases: multiple sclerosis, sarcoidosis, type 1 and 2 diabetes mellitus, Hashimoto’s thyroiditis,
and Parkinson’s disease (90–96). Over the years, several studies
have investigated the role of MAP in CD with conflicting results
(4, 97–100). MAP has been isolated from CD patients by culturing blood, breast milk, and tissue biopsy samples, and samples
were shown positive for IS900 by PCR (101–103). Also by this
method, MAP was present in the gut of 92% of CD patients and
26% of control individuals (98). Humans are exposed to MAP
from various sources that could be contaminated from infected
animals, such as drinking water with feces, milk, etc. (104). In
the United Kingdom, a study revealed that even after pasteurization, MAP was detected by IS900 PCR in 7% of retail milk for
human consumption (105). Nonetheless, this is highly dependent
on the pasteurization method since the application of a standard high-temperature short-time pasteurization results in the
destruction of MAP (106). However, some bacteria survived the
sub-pasteurization heat treatment at lower temperatures used for
cheese manufacture. Thus, though humans are widely exposed
to MAP, susceptible individuals with a compromised immune
system, due to other illness or genetic factors, may be at higher
risk for infection and disease. In these individuals, MAP may
survive and multiply inside gut macrophages leading to immune
dysregulation and inflammation of the intestinal wall resulting
in a “leaky gut” (http://www.crohnsmapvaccine.com). Microbes
and food materials penetrate the leaky gut causing massive wall
inflammation leading to chronic inflammatory bowel disease.
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Currently a combination of anti-inflammatory, antimycobacterial, and immunosuppressant drugs are used or in
trials for CD treatment. Initially, only anti-tuberculosis drugs
were used for treatment of MAP infections in humans, but the
results were not promising. Later macrolides (e.g., azithromycin
and erythromycin), rifabutin, and clofazimine have been used
with limited success, but the treatment regimen is very lengthy
(2, 66, 107–109). A comprehensive study evaluated culture
methods for the determination of MAP in vitro drug susceptibility and concluded that the BACTEC™ MGIT™ system was
more rapid and reliable (110). In addition, in vitro studies using
drug combinations of anti-microbials and immunomodulators
displayed synergistic effects that could be applied to CD treatment (111). Therefore, more studies are needed to identify novel
drugs and/or targets for the development of better therapeutics
against MAP to shorten and simplify the treatment. Regarding
MAP pathogenesis, the European Food Safety Authority has
conducted a thorough study and indicated that MAP is eligible
to be listed for Union intervention based on Article 5(3) of the
Animal Health Law (112). Several species of mammals and birds
were listed as susceptible species, including Bovidae, Cervidae,
and Leporidae, but there was no consensus on the zoonotic risk
of MAP in the context of human diseases, such as CD.

K-10 and MAH, with additional differences involving duplications, deletions, and polymorphisms. Based on these analyses,
ovine isolates seem to be an intermediate in the evolution of
MAP bovine strains from MAH human strains (115), although
this is not definitely established (121). However, the more closely
related bovine and human isolates (118, 120) may be the latest
strains that diverged in evolution acquiring specific host adaptations in their genomes.

TRANSPOSON MUTAGENESIS
The identification and functional analysis of genes involved in
the pathogenesis of MAP requires molecular genetic tools to
manipulate its genome. Because the MAP cell wall is very thick
and impermeable, it is difficult to introduce plasmid vectors. The
shuttle plasmid vector pMV262 carrying a mycobacterial origin
of replication (oriM) and an Escherichia coli origin of replication
(oriE) have been used to transform MAP (123). However, the
transformation efficiency was very low; therefore, a phagemediated transduction process was developed to introduce
DNA into MAP (124). Shuttle phasmids (phagemids) carrying the mycobacteriophage TM4 (125) and an E. coli cosmid
have been widely used for the genetic manipulation of MAP.
More recently, the generation of MAP mutant libraries using
transposon mutagenesis has been the major approach to define
virulence determinants and identify genes that are essential
and non-essential (126). Two types of transposons have been
extensively used in mycobacteria to generate random mutant
banks: (i) IS1096-derived and (ii) Himar1-derived transposons
(Figure 3).
Tn5367 (GenBank Accession KM232614) was the first transposon widely used in mycobacteria including MAP (126–128).
This transposon (3,381 bp) carries a kanamycin-resistant drug
marker (aph), and the IS1096 transposase (tnpA) and resolvase
(tnpR). This transposon has the transposase within the transposed element (126) resulting in a relatively high transposition
frequency (ca. 1.0 × 10−5), at least in Mycobacterium smegmatis
(129). Tn5367 transposes by a cutting and paste mechanism
(130) and may insert in another gene creating either a wildtype or mutated gene, depending on precise or imprecise excisions, in the location of the original insertion. The transposon
can be delivered into Mycobacterium by the thermosensitive
phasmid derivative of mycobacteriophage TM4 (126). Since the
IS1096 transposase is located within the transposed element,
the corresponding MAP mutants may not be stable enough to
conduct long-term in vivo experiments where bacilli multiply
to large numbers. An improved IS1096-derived transposon,
Tn5370 (GenBank Accession KM232615), was constructed
by removing ORFs dispensable for transposition (e.g., tnpR),
therefore, reducing the size to 2,295 bp (128, 130). More
over, the transposase was engineered into the phasmid outside of
the transposable element. Thus, Tn5370, as opposed to Tn5367,
generates stable mutants upon transposition. This transposon
has the advantage of possessing a hygromycin (hyg) marker
within the transposable element outflanked by the γ-δ resolvase.
This construction allows for the excision of the drug marker
and the generation of unmarked transposon insertion mutants.

GENOMICS
The MAP bovine strain K-10 genome has been sequenced, annotated, and re-examined by optical mapping (22, 113, 114). The
updated K-10 genome is 4,829,781 bp encoding 4,350 proteinencoding ORFs with a 69.3% GC content. In the genome, about
60% of the ORFs have similar sequences in microbial genetic
databases, but only approximately 35% have well predicted or
identified functions (115). Nonetheless, about 75% of the MAP
genes have counterparts in Mycobacterium tuberculosis with
39 predicted proteins that are unique to MAP. This genome
possesses a high redundancy rate due to gene duplications,
particularly for those involved in lipid metabolism and redox
processes. Gene functions include 150 transcriptional regulators, 16 polyketide synthesis, 14 two-component regulatory
systems, 16 serine–threonine protein kinases, 8 mammalian cell
entry (mce), 20 insertion elements, and 5 putative prophages.
Sequencing also iden
tified and mapped genes involved in
glycolysis, pentose phosphate pathway, tricarboxylic acid cycle,
and glyoxylate cycle (116). Important differences between the
genomes of K-10 and M. tuberculosis human strain H37Rv
include the following: (i) no intact Pro-Glu-polymorphic
GC-rich sequences (PE-PGRS) genes, (ii) 47 fewer Pro-Pro-Glu
(PPE) genes in M. tuberculosis (117), and (iii) the presence of a
truncated salicyl-AMP ligase gene (mtbA) which may explain
the MAP mycobactin biosynthesis defect discussed earlier (22).
Other MAP strains with complete sequences include the
human strain MAP4 (118) and another bovine strain JII-1961
(119). Partial MAP genomic sequences include 10-4404,
2015WD-1, 2015WD-2, ATCC19698, JQ5, S5, S397, JIII-386, and
several human isolates (118, 120–122). The MAP ovine genomes
of strains S397 and JIII-386 differ by one inversion to the MAH
human strain 104, while two inversions are detected between
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Figure 3 | Structure of mycobacterial transposons utilized to generate random mutant libraries. Inverted repeat (IR) for Tn5367 or Tn5370 (filled triangle),
or Himar1-derived transposon (striped triangle); tnpR, IS1096 resolvase; aph, kanamycin-resistant gene; tnpA, IS1096 transposase; res, resolution site for
transposon gamma-delta; hyg, hygromycin resistant gene; and C9 Himar1, Himar1 transposase.

However, neither Tn5367 nor Tn5370 transposes randomly in
mycobacteria (127, 130).
Himar1-derived transposons have also been used to generate
random mutant libraries in M. tuberculosis and MAP (131–134).
The Himar1 transposon (MycoMarT7) was engineered into the
same TM4 phasmid derivative described above. This vector carries the highly active C9 Himar1 transposase outside the inverted
repeats, thus yielding stable mutants. In addition, this vector carries the aph drug marker and a T7 promoter that reads outward
to facilitate identification of insertion sites by in vitro transcrip
tion and cDNA synthesis (131). The major advantage of the
Himar1 derivative is the almost fully random recognition sequence
(5′-TA-3′) versus the recognition sequence of IS1096-derived
transposons (5′-NNPy(A/T)A(A/T)NN-3′) showed experimentally to have a transposition bias in both M. tuberculosis and
MAP (127, 130). Most of the MAP transposon mutant libraries
were made with Tn5367 (127, 128, 135, 136) and fewer libraries
have been constructed using the Himar1-derived transposon
MycoMarT7 (132, 133). Our group has constructed a Himar1
library for MAP and used it to demonstrate random genomic
insertions (134).

tools. MAP genomics has many applications, such as molecular
detection, determining the molecular evolution of MAP as a
pathogen, and identifying virulence determinants, drug targets,
attenuation targets for vaccine development, and/or diagnostic
antigens. Several strategies were used to mine the MAP genome
for virulence determinants or important diagnostic antigens
(137–139). One approach relied on identifying MAP genes with
known M. tuberculosis homologs known to play important roles
in pathogenesis (140, 141). Many of these studies described below
have generated deletion mutants to identify the role of these
genes in pathogenesis. Usually, phasmids are used to deliver the
allelic exchange substrate into MAP to produce the desired gene
deletion by homologous recombination. For example, based
on the attenuation of M. tuberculosis leuD mutants (140), the
corresponding MAP leuD mutants were constructed by allelic
exchange, characterized by carbon and nitrogen source utilization, and showed to be attenuated in mice (142, 143). Likewise, a
mutant of MAP lipN was constructed and displayed lower levels
of colonization in mice compared to the wild-type strain (144).
Similarly, lsr2, pknG, and relA deletion mutants were generated
(145) and later in vivo mice studies revealed that relA mutants
were immunogenic, but had decreased pathogenicity (146).
Other studies constructed sigH and sigL deletion mutants, infecting bovine macrophages and mice to demonstrate that this gene
plays a role in pathogenesis (147, 148). Recently, sigH and lipN
deletion mutants were validated as promising live-attenuated
vaccine candidates in goats (149). Nonetheless, these meritorious
studies are not comprehensive since genetic islands were identified in the MAP genome demonstrating a gene organization
different from the closely related MAH (150). Indeed, differences

MOLECULAR GENETICS IN THE
POST-GENOMICS ERA: CANDIDATE
VACCINE APPLICATIONS
Our understanding of MAP pathogenesis has greatly improved
based on the completion of the MAP K-10 genome sequence, and
the availability of advanced molecular biology and bioinformatics
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in gene organization may lead to a context-dependent function
(e.g., even homologous genes in MAP and MAH may play dif
ferent roles in pathogenesis). This effect is further compounded
by findings indicating host genome adaptations (115).
In the context of vectored subunit vaccines, success has been
achieved in the expression of MAP antigens in Lactobacillus
salivarius using a codon optimization strategy (151, 152).
Multi-antigen virally vectored vaccines were also engineered
and tested in mice and cattle. In this context, the vaccine designated HAV is a fusion of two secreted and two cell surface
MAP proteins whose DNA coding sequence was inserted into
the human adenovirus 5 and Modified Vaccinia Ankara delivery
vectors. Vaccination of naive C57BL/6 mice resulted in a highly
immunogenic response with significant levels of IFN-γ and a
humoral response against the recombinant antigens (153). The
vaccine provided moderate protection against challenge. This
vaccine was also tested in cattle with promising results being
well tolerated, showing no cross-reactivity against bovine
tuberculin, providing some protection against challenge in a
calf model and eliciting CD4+, CD8+ IFN-γ producing T-cell
populations and, upon challenge, developed early specific Th17
T-cells (154). In addition, a non-recombinant Lacotbacillus casei
used as a probiotic immunomodulated and reduced pathology
in a mouse MAP infection model (155). Moderate success has
been attained with recombinant MAP Hsp70 proteins resulting
in a reduction of bacterial shedding upon experimental infection without compromising the diagnosis of bovine tuberculosis
(156, 157) and showed some promise as a therapeutic vaccine in
cattle (158). Lipoarabinomannan-enriched glycolipid extracts
used as potential subunit vaccines against MAP yielded a
pro-apoptotic response in bovine macrophages and reduced
shedding (159, 160). Studies have also been conducted with
purified antigens or antigen cocktails. For example, superoxide
dismutase and antigen 85B were shown to elicit T-cell responses
consistent with protection in mice (161, 162). These results were
further advanced using DNA vector vaccines (145). Various
MAP protein cocktails were also tested in mice and cattle,
showing reduced tissue burden (163), and INF-γ and humoral
responses, respectively (164). Nonetheless, the extensive experience of researchers in the human tuberculosis vaccine field has
led to the consensus that live-attenuated vaccines are the best
approach for vaccination against mycobacterial diseases (83).
Gene expression in MAP is complex and global regulation has
been associated with 19 putative sigma factors with 12 belonging
to common mycobacterial gene families. Specific sigma factors
may be involved in the expression of survival and virulence genes
(165). In addition, MAP virulence determinants are regulated by
the LuxR–LuxI quorum sensing system (166). Transcriptomic
analysis has been applied extensively and these studies generated
large expression databases under conditions of environmental
stress (144), iron limitation (167), intracellular survival within
BMDM, tissue localization in vivo (168), and ligated jejuno-ileal
loops (58, 59). Some differentially regulated genes such as atpC,
clpB, dnaJ, dnaK, groEL2, infB, kdpE, mbtC, and pmmA correspond to essential genes in M. tuberculosis (131, 144, 169). Other
genes identified as non-essential more likely to be involved in
pathogenesis rather than general physiological functions: aceAB,
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clpX, relA, htpX, lipL, lipN, and lpqP. Indeed M. tuberculosis
homologs of lipL, lipN, aceAB, and lpqP were also identified as
being required for intracellular survival within macrophages by
a genetic approach (170). Another insight from transcriptomic
studies revealed significant differences in gene expression
with MAP metabolic genes being shut down in tissues, while
phagocytic cells upregulated genes involved in iron acquisition
and intracellular survival (168). Interestingly, the analysis of
databases from different studies does not reveal any significant
correlations. Moreover, the fold-changes in gene expression
levels differed widely from one study to another. Nonetheless,
except for specific and restricted conditions, a common feature
is that approximately 20–25% of the genes in the MAP genome
change their expression levels based on the condition. Likewise
for M. tuberculosis, little correlation was observed among genes
that were up- or downregulated in macrophages or infected mice,
and those identified by a genetic approach as being required for
survival in macrophages and mice (170, 171). In retrospect,
these results are not surprising as genetic methods establish
gene requirements for a certain condition as an outcome of a
cumulative selection process during the infection, independent
of their mode of regulation. In this context, transcriptomic
approaches may miss a significant number of constitutively or
transiently expressed genes involved in pathogenesis. As transcriptomic approaches require discrete rather than continuous
samplings, most appropriate time points could be missed.
Transposon mutagenesis is another strategy that has been
used to identify MAP virulence genes. In this approach, genes
are disrupted using random transposition to generate a mutant
library where each mutant is marked with a transposon. Mutants
are then screened under different in vitro and in vivo conditions for the functional analysis of genes. Mutants that have a
mutation in genes that are essential will not survive. A library
of 5,060 Tn5367 transposon mutants was generated to apply a
transposon–chromosome junction site sequencing protocol
in order to identify the disrupted genes (127). They analyzed
1,150 mutants and identified 970 unique insertion sites. Based
on sequencing analysis, they selected 11 mutants for mouse
infection experiments and identified some potential virulence
genes (gcpE, pstA, kdpC, papA2, impA, umaA1, and fabG2_2).
In our study, we generated and screened a MAP transposon
library of 13,536 mutants, identifying genes potentially involved
in pathogenesis (e.g., MAP1152, MAP1156, MAP1566, and lsr2)
(128). Another study used the Himar1 transposon in MAP to
isolate 111 mutants attenuated in BMDM from a random screen
of 2,290 (132). Unfortunately, all of these studies have limitations: (i) the screening and analysis methods used are laborious
and time consuming, especially for slow-growing MAP and
(ii) the library used for screening is partial because of transposon
bias (134) so it is not possible to perform the functional analysis
of the entire MAP genome. To overcome these limitations, it is
necessary to generate a comprehensive MAP mutant library and
design new and more robust approaches to perform global gene
functional analysis.
Transposon site hybridization (TraSH) has been applied for
the global analysis of the M. tuberculosis genome (131). In this
method, a high-density transposon mutant library is generated
7
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and the mutants are pooled. DNA microarray is then applied
to map all transposon insertion sites. This approach has some
limitations, such as poor resolution, limited dynamic range,
and the requirement to develop DNA microarrays. Recently, a
new method has been established based on next-generation
deep sequencing to analyze the essentiality of genes on a wholegenome basis called transposon sequencing (Tn-Seq) (172).
Tn-Seq involves the generation of a comprehensive mutant
library using a transposon that inserts randomly without any
biases. The mutants are pooled to isolate genomic DNA so
the transposon chromosomal junctions can be amplified and
sequenced using an Illumina or another suitable platform. This
approach has been applied for M. tuberculosis to define essential
genes under various conditions (173, 174). More recently, the
Tn-Seq method was used to classify MAP essential genes by
generating a pool of approximately 100,000 Himar1 transposon
mutants (133). However, we have demonstrated that Himar1
transposons recombine with significant loci-dependent biases,
making these collections highly underrepresented (134). The
application of the Tn-Seq system to a highly saturated Himar1
transposon mutant library will overcome these limitations and
provide a global approach to the identification of MAP essential
genes and virulence determinants.

MAP taxonomy and cultivation. The main mechanisms of pathogenesis related to the invasion of the intestinal epithelium and
the underlying humoral and cellular responses are discussed.
Infection models are concisely summarized thereafter. The article
then shifts to the multiple methods of JD diagnosis, including
acid-fast stain, culture, PCR, and the use of ELISA to detect the
antibody and INF-γ responses. The control of JD is explained
in the context of commercially available vaccines and their
efficacies. This section also includes results of a recent multiinstitutional live-attenuated JD vaccine testing program. MAP
zoonotic potential is described based on the diagnostic methods
used to detect MAP in human samples along with the various
treatment options. Subsequently, we focus on genomics, including the analysis of bovine and ovine genome sequence isolates.
This leads to the transposon mutagenesis section where we define
the transposons and vectors used and summarize the results
obtained with mutant banks. The final post-genomic section
discusses the construction of new attenuated mutants by deletion
mutagenesis and their vaccine potential. We also discuss antigen
and antigen cocktails that have been suggested for subunit vaccine formulations. The manuscript concludes with the discussion
of gene expression, global regulators, methods of wide genomic
analysis, such as TraSH mutagenesis and Tn-Seq analysis, and our
perspective on current and future vaccine efforts.
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